1. Home
  2. LYRA vs INBS Comparison

LYRA vs INBS Comparison

Compare LYRA & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • INBS
  • Stock Information
  • Founded
  • LYRA 2005
  • INBS 2016
  • Country
  • LYRA United States
  • INBS United States
  • Employees
  • LYRA N/A
  • INBS N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • INBS Medical Specialities
  • Sector
  • LYRA Health Care
  • INBS Health Care
  • Exchange
  • LYRA Nasdaq
  • INBS Nasdaq
  • Market Cap
  • LYRA 11.3M
  • INBS 11.7M
  • IPO Year
  • LYRA 2020
  • INBS N/A
  • Fundamental
  • Price
  • LYRA $6.85
  • INBS $1.55
  • Analyst Decision
  • LYRA Hold
  • INBS
  • Analyst Count
  • LYRA 1
  • INBS 0
  • Target Price
  • LYRA $16.00
  • INBS N/A
  • AVG Volume (30 Days)
  • LYRA 14.2K
  • INBS 105.5K
  • Earning Date
  • LYRA 08-12-2025
  • INBS 11-06-2025
  • Dividend Yield
  • LYRA N/A
  • INBS N/A
  • EPS Growth
  • LYRA N/A
  • INBS N/A
  • EPS
  • LYRA N/A
  • INBS N/A
  • Revenue
  • LYRA $770,000.00
  • INBS $3,052,532.00
  • Revenue This Year
  • LYRA N/A
  • INBS $778.48
  • Revenue Next Year
  • LYRA $123.46
  • INBS N/A
  • P/E Ratio
  • LYRA N/A
  • INBS N/A
  • Revenue Growth
  • LYRA N/A
  • INBS N/A
  • 52 Week Low
  • LYRA $3.81
  • INBS $1.10
  • 52 Week High
  • LYRA $37.50
  • INBS $3.00
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 42.34
  • INBS 48.52
  • Support Level
  • LYRA $6.91
  • INBS $1.40
  • Resistance Level
  • LYRA $7.50
  • INBS $1.70
  • Average True Range (ATR)
  • LYRA 0.33
  • INBS 0.11
  • MACD
  • LYRA 0.06
  • INBS 0.02
  • Stochastic Oscillator
  • LYRA 16.18
  • INBS 53.85

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Share on Social Networks: